急性髓系白血病患者miRNA-509表达水平与临床特征及预后的关系  

Correlation of miRNA-509 expression level with the clinical characteristics and prognosis in acute myeloid leukemia patients

作　　者：沈洋灵 岳延华 顾伟英[1] 贺白[1] Shen Yangling;Yue Yanhua;Gu Weiying;He Bai(Department of Hematology,the Third Affiliated Hospital of Soochow University,the First People's Hospital of Changzhou,Changzhou 213000,China)

机构地区：[1]苏州大学附属第三医院、常州市第一人民医院血液科,常州213000

出　　处：《白血病．淋巴瘤》2022年第12期710-715,共6页Journal of Leukemia & Lymphoma

摘　　要：目的探讨急性髓系白血病(AML)中miRNA-509(miR-509)表达水平与患者临床特征及预后的关系。方法从癌症基因组图谱(TCGA)数据库中下载162例根据世界卫生组织(WHO)分型标准新诊断的AML(非M3型)患者资料,生存数据统计截至2013年4月30日;从TCGA-LAML中下载这些患者的RNA-seq表达谱。根据治疗方式分为化疗组和异基因造血干细胞移植(allo-HSCT)组,各组根据miR-509中位相对表达量又分为高表达和低表达亚组,比较各亚组患者的临床特征;比较化疗组和allo-HSCT组miR-509相对表达量对AML患者总生存(OS)及无事件生存(EFS)的影响。将162例患者根据总体miR-509中位相对表达量分为高表达组和低表达组,各组按治疗方式又分为化疗亚组和allo-HSCT亚组,比较各亚组患者OS及EFS的差异。结果162例患者分为化疗组90例和allo-HSCT组72例;两组根据miR-509相对表达量中位数(化疗组为14.07,allo-HSCT组为14.85)分为高表达亚组及低表达亚组。化疗组和allo-HSCT组高表达亚组和低表达亚组不同性别、初诊时白细胞计数、骨髓及外周血原始/幼稚细胞比例和法、美、英协作组(FAB)分型的患者比例差异均无统计学意义(均P>0.05);化疗组低表达亚组中预后中等患者比例高于高表达亚组[68.9%(31/45)比42.2%(19/45),χ^(2)=6.48,P=0.011],其余危险度分层患者比例两亚组间差异均无统计学意义(均P>0.05)。90例化疗组患者中,miR-509低表达组(45例)和高表达组(45例)中位OS时间分别为10.2个月和6.7个月,5年OS率分别为17.9%和17.0%,5年EFS率分别为16.9%和18.2%;两组OS及EFS差异均无统计学意义(P=0.575,P=0.436)。72例allo-HSCT组患者中,miR-509低表达亚组患者OS及EFS均优于高表达亚组,差异有统计学意义(P=0.006,P=0.022)。将162例患者根据miR-509相对表达量中位数(14.19)分为低表达组(81例)和高表达组(81例),在miR-509低表达患者中,allo-HSCT亚组的OS优于化疗亚组,差异有统计学意义(Objective To explore the correlation of miRNA-509(miR-509)expression level with the clinical characteristics and prognosis in acute myeloid leukemia(AML)patients.Methods The RNA-seq expression data and clinical data of 162 newly diagnosed AML patients(non-M3 subtype)based on the World Health Organization(WHO)classification were obtained from the Cancer Genome Atlas(TCGA)database(Project ID:TCGA-LAML).The final follow-up time was April 30th,2013.According to the different treatment methods,all cases were firstly divided into the chemotherapy group and allogeneic hematopoietic stem cell transplantation(allo-HSCT)group.Each group was subdivided into high miR-509 group and low miR-509 group according to the median relative expression of miR-509,respectively;the clinical characteristics of both groups were analyzed.The effects of miR-509 relative expression level on overall survival(OS)and event-free survival(EFS)of AML patients in chemotherapy group and allo-HSCT group were compared.On the other hand,cases were divided into two groups based on the median relative expression level of miR-509,then each group were further divided into the chemotherapy subgroup and allo-HSCT subgroup according to different treatment methods.The differences of OS and EFS of AML patients with different miR-509 expression in chemotherapy and allo-HSCT subgroups were compared.Results All the 162 AML patients were firstly divided into chemotherapy group(90 cases)and allo-HSCT group(72 cases).Each group was subdivided into high miR-509 and low miR-509 group according to the median relative expression of miR-509(chemotherapy group:14.07,allo-HSCT group:14.85),respectively.There were no statistically significant differences in the proportion of patients with gender,white blood cell count at initial diagnosis,bone marrow blast/naive cells ratio,peripheral blood blast/naive cells ratio and France-America-British(FAB)subtype between high miR-509 and low miR-509 subgroups in chemotherapy subgroup and allo-HSCT subgroup(all P>0.05).In the chemotherap

关 键 词：白血病 髓样 急性 微RNAS 医学信息学 预后 

分 类 号：R733.71[医药卫生—肿瘤]